top of page
Invclicosta header.png
LES_Activo_Moderado_Grave.jpeg

Active Systemic Lupus Erythematosus

The Centro de Investigación de la Clínica de la Costa invites you to participate in a monoclonal antibody treatment study for moderately to severely active SLE.

Requirements:

  • To be over 18 years old

  • Diagnosis of SLE at least 6 months ago

  • Moderately to severely active SLE and positive for autoantibodies

  • Must have received standard therapy for SLE for at least 3 months

Congestive Heart Failure

The Centro de Investigación de la Clínica de la Costa invites you to learn about and participate in the study of new treatments for congestive heart failure.

Requirement:

  • To have heart disease

Crohn's Disease

The Centro de Investigación de la Clínica de la Costa invites you to participate in a treatment study for moderate to severe disease.

Requirements:

  • To be over 18 years old

  • Diagnosis of Crohn's disease confirmed by colonoscopy

  • To have symptoms of the disease in the last 3 months

anemia falciforme.jpg

Sickle Cell Disease

The Centro de Investigación de la Clínica de la Costa invites you to learn about and participate in the treatment study for the prevention of vaso-occlusive crises.

Requirements:

  • To be over 12 years old

  • Diagnosis of sickle cell anemia

  • History of vaso-occlusive crises (2 to 10 crises in the last 12 months)

Lupus Nephritis

The Centro de Investigación de la Clínica de la Costa invites you to participate in a monoclonal antibody treatment study.

Requirements:

  • To be between 18 and 75 years old

  • Diagnosis of class III, IV or IV lupus nephritis by kidney biopsy

  • Diagnosis of SLE

  • 24-hour urine proteinuria greater than 1 g

cancer_de_prostata.jpeg

Prostate Cancer

The Centro de Investigación de la Clínica de la Costa invites you to learn about and participate in the treatment study for prostate cancer.

Requirements:

  • To be over 18 years old

  • To have a histologically or cytologically confirmed adenocarcinoma of the prostate

  • Having a progression of prostate cancer while on ADT (or after bilateral orchiectomy) within 6 months

  • There is other eligibility criteria*

cancer_cabeza_y_cuello.png

Head and Neck Cancer

The Centro de Investigación de la Clínica de la Costa invites you to participate in a treatment study for head and neck cancer.

Requirements:

  • To be over 18 years old

  • To have a recent histologically confirmed diagnosis of resectable non-metastatic squamous cell carcinoma (HNSCC)

  • There is other eligibility criteria*

Cáncer gastroesofágico.jpeg

Gastroesophageal Cancer

The Centro de Investigación de la Clínica de la Costa invites you to learn about and participate in the treatment study for gastroesophageal cancer.

Requirements:

  • To be over 18 years old

  • To have a confirmed diagnosis by histologic and/or cytologic evidence of unresectable or metastatic gastroesophageal adenocarcinoma

  • There is other eligibility criteria*

Cancer_renal.jpeg

Kidney Cancer

The Centro de Investigación de la Clínica de la Costa invites you to participate in a treatment study for kidney cancer.

Requirements:

  • To be over 18 years old

  • To have a histologically confirmed diagnosis of stage IV RCC

  • Having not received prior systemic treatment for advanced ccRCC

  • To have measurable disease per RECIST 1.1

  • There is other eligibility criteria*

Tumores sólidos.png

Solid Tumors

The Centro de Investigación de la Clínica de la Costa invites you to learn about and participate in the treatment study for solid tumors.

Requirements:

  • To be over 18 years old

  • To have a histologically or cytologically confirmed advanced (metastatic or unresectable) solid tumor

  • Main tumors: bladder, biliary, cervical, endometrial, esophageal, gastric, head and neck

  • There is other eligibility criteria* 

Results of Our Clinical Research

Molnupiravir_Covid-19_research.jpeg

Molnupiravir

Molnupiravir: Antiviral treatment from the pharmaceutical company Merck Sharp & Dohme, studied at the Clínica de la Costa Research Center, is approved by INVIMA for the treatment against COVID-19.

molnupiravir_clinical_research.webp
clover_vaccine_research.jpeg

Clover Vaccine

The Clover Pharmaceuticals COVID-19 vaccine study was developed in 31 entities, one of them being the Clínica de la Costa Research Center.

 

Clover_Pharmaceuticals_Research.jpeg
Nefritis_Lupica_Clinical_Trial.jpeg

Kidney Diseases

The Clínica de la Costa, its Research Center and the Simón Bolívar University have treated more than 500 people with Lupus and renal compromise. Highlighting the study on Lupus Nephritis from the Novartis Pharmaceutical House.

Nefritis_Lupica_research.jpg
bottom of page